MetaVia earnings release, May 14, 2026

MetaVia Inc. (MTVA) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

​

​

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

​

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit

​

Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step) Regimens; Data Expected in Fourth Quarter 2026

​

CAMBRIDGE, Mass., May 14, 2026 – MetaVia Inc.

(Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.

“We continued to build strong momentum in the first quarter of 2026 and most recently, as highlighted by the on-time dosing of the first patient in Part 3 of our Phase 1 clinical trial of DA-1726 for obesity, which followed closely on the heels of receiving IRB approval,” said Hyung Heon Kim, Chief Executive Officer of MetaVia. “In this part of the trial, we are evaluating higher doses through optimized titration regimens, including a one-step escalation to 48 mg and a two-step escalation to 64 mg. This strategy is intended to safely reach higher therapeutic doses with improved tolerability, which could represent a meaningful advantage compared to currently marketed therapies that require longer, more gradual titration. Our January financing provides the capital to support the execution of this study, and we look forward to reporting data from Part 3 in the fourth quarter of 2026.”

“This trial is designed to build on the compelling results reported in January from the 8-week, non-titrated 48 mg cohort, which demonstrated robust early weight loss of 9.1%, statistically significant reductions in waist circumference, meaningful improvements in glucose control and direct liver benefit, all with a favorable safety and tolerability profile. Based on these results, we believe DA-1726 has the potential to establish a best-in-class profile in obesity and broader cardiometabolic disease, driven by its differentiated dual GLP-1/glucagon mechanism. We also look forward to presenting additional data from the Phase 1 48 mg dose cohort on the direct liver benefit of DA-1726 at the European Association for the Study of the Liver (EASL) Congress 2026.”

First Quarter 2026 and Subsequent Highlights

Anticipated Clinical Milestones

First Quarter Financial and Operating Results

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.

In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited - In thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating expensesResearch and development2,1012,327
Operating expensesGeneral and administrative1,9241,559
Operating expensesTotal operating expenses4,0253,886
Operating expensesLoss from operations-4,025-3,886
Other incomeGain from change in fair value of warrant liabilities11787
Other incomeInterest income, net85128
Other incomeTotal other income202215
Other incomeLoss before income taxes-3,823-3,671
Other incomeNet loss-3,823-3,671
Other incomeLoss per share of common stock, basic and diluted-0.79-3.93
Other incomeWeighted average shares of common stock, basic and diluted4,859,567933,109

Balance Sheet

(Unaudited - In thousands, except share and per share amounts)

As of – March 31, 2026As of – December 31, 2025
Current assetsCash and cash equivalents13,73110,278
Current assetsPrepaid expenses and other current assets431597
Current assetsTotal current assets14,16210,875
Current assetsProperty and equipment, net1217
Current assetsRight-of-use asset193210
Current assetsOther assets2121
Current assetsTotal assets14,38811,123
Current liabilitiesAccounts payable1,0071,060
Current liabilitiesClinical trial accrued liabilities62779
Current liabilitiesAccrued expenses and other current liabilities456993
Current liabilitiesWarrant liabilities19136
Current liabilitiesRelated party payable3,0123,312
Current liabilitiesLease liability, short-term7168
Current liabilitiesTotal current liabilities5,1925,648
Current liabilitiesLease liability, long-term123142
Current liabilitiesTotal liabilities5,3155,790
Stockholders’ equityCommon stock, $0.001 par value per share, 100,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 5,164,370 and 2,308,294 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively52
Stockholders’ equityAdditional paid–in capital161,721154,161
Stockholders’ equityAccumulated deficit-152,653-148,830
Stockholders’ equityTotal stockholders’ equity9,0735,333
Stockholders’ equityTotal liabilities and stockholders’ equity14,38811,123
Full release

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", “potential”, "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia’s ability to execute... (truncated)linical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

​

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer

+1-857-299-1033 marshall.woodworth@metaviatx.com

​

Rx Communications Group

Michael Miller

+1-917-633-6086 mmiller@rxir.com

​

- Tables to Follow -

​

MetaVia Inc.

Condensed Consolidated Balance Sheets

(Unaudited - In thousands, except share and per share amounts)

​

​

​

​

MetaVia Inc.

Condensed Consolidated Statements of Operations

(Unaudited - In thousands, except share and per share amounts)

​

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · MetaVia earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.